Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Revolo Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 15, 2021
CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.